Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Targeted Osteoarthritis Therapy Using Stem Cell Membrane-Derived Nanovesicles for Transforming Growth Factor-Beta (TGF-B) Signaling Control

EF 2025-26

Résumé
Osteoarthritis (OA) is a very common joint disease in which the cartilage degrades and the bone remodels irregularly, causing significant pain. Most treatment options focus on pain relief rather than managing the condition itself. As such, there is a need to develop a novel OA treatment that targets the joint as a whole and effectively reduces OA progression. In OA, the molecular signaling of transforming growth factor-B (TGF-B) is dysregulated, contributing to the classic OA symptoms described earlier. Restoring proper TGF-B signaling in the joint is therefore a promising therapeutic target. Within the joint, irregular TGF-B signaling is very cell-specific, involving ALK1 receptors in the cartilage and ALK5 receptors in the bone. Delivery of antisense oligonucleotides (ASOs) will interrupt the translation process thereby reducing ALK1 and ALK5 receptor expression. However, ASOs will be designed to be specific to either ALK1 or ALK5 and must therefore be specifically delivered to either cartilage or bone cells, respectively. To do so, the ALK1- or ALK5-specific ASOs will be encapsulated in mesenchymal stem cell-derived nanovesicles that have aptamers on their surface. Aptamers are structures that can specifically bind to certain cell types based on their make-up. They will therefore be selected to bind to either cartilage or bone cells to enable the targeted delivery of the desired ASO. Further, the use of mesenchymal stem cell membrane-derived nanovesicles is due to their known ability to reduce inflammation and promote regeneration in OA joints. Overall, the proposed OA multi-faceted treatment involves the targeted delivery of ASOs to the bone and cartilage using bioactive membrane-derived nanovesicles for the modulation of irregular TGF-B signaling.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573219
Name
Nasrallah Yara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeted Osteoarthritis Therapy Using Stem Cell Membrane-Derived Nanovesicles for Transforming Growth Factor-Beta (TGF-B) Signaling Control
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antisense Oligonucleotides (Asos); Intra-Articular Therapeutic Delivery; Membrane-Derived Nanovesicles; Mesenchymal Stem Cells (Mscs); Osteoarthritis; Transforming Growth Factor-Beta (Tgf-B)
Abstract
Osteoarthritis (OA) is a very common joint disease in which the cartilage degrades and the bone remodels irregularly, causing significant pain. Most treatment options focus on pain relief rather than managing the condition itself. As such, there is a need to develop a novel OA treatment that targets the joint as a whole and effectively reduces OA progression. In OA, the molecular signaling of transforming growth factor-B (TGF-B) is dysregulated, contributing to the classic OA symptoms described earlier. Restoring proper TGF-B signaling in the joint is therefore a promising therapeutic target. Within the joint, irregular TGF-B signaling is very cell-specific, involving ALK1 receptors in the cartilage and ALK5 receptors in the bone. Delivery of antisense oligonucleotides (ASOs) will interrupt the translation process thereby reducing ALK1 and ALK5 receptor expression. However, ASOs will be designed to be specific to either ALK1 or ALK5 and must therefore be specifically delivered to either cartilage or bone cells, respectively. To do so, the ALK1- or ALK5-specific ASOs will be encapsulated in mesenchymal stem cell-derived nanovesicles that have aptamers on their surface. Aptamers are structures that can specifically bind to certain cell types based on their make-up. They will therefore be selected to bind to either cartilage or bone cells to enable the targeted delivery of the desired ASO. Further, the use of mesenchymal stem cell membrane-derived nanovesicles is due to their known ability to reduce inflammation and promote regeneration in OA joints. Overall, the proposed OA multi-faceted treatment involves the targeted delivery of ASOs to the bone and cartilage using bioactive membrane-derived nanovesicles for the modulation of irregular TGF-B signaling.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nasrallah, Yara
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~